Northstar Neuroscience, Inc. (NSTR)
A medical device company focused on developing and commercializing innovative neurostimulation therapies for a range of neurological diseases and disorders.
Recs
Northstar Neuroscience is a medical device company committed to providing neurostimulation therapies for people who suffer from stroke and other neurological disorders. The company's technology is designed to deliver electrical stimulation to the outermost layer of the brain, called the cortex, in a process referred to as cortical stimulation.
This appears, at least on the surface (no pun intended), to be a safer 'experimental' therapy than the much publicized 'experimental' therapy of Deep Brain Stimulation.
So far results are promising and to my mind (again no pun intended), very exciting.
It's a risky investment for sure, as are most experimental therapies, but one I'm willing to take a chance on. Perhaps more out of hope (non financial), than anything else.
Recs
Losing money like crazy,not expected to make profit in next 2 years. Huge insider holdings on options. NO insider buying. Hmmmm be patient and watch it go down.Great 2 year short holding.Sell now before it goes down more. PPP way too bloated.
Recs
Northstar Neuroscience is a medical device company committed to providing neurostimulation therapies for people who suffer from stroke and other neurological disorders. The company's innovative technology is designed to deliver targeted electrical stimulation to the outermost layer of the brain, called the cortex, in a process referred to as cortical stimulation. It is also studying therapeutic applications for other neurological conditions including stroke-related aphasia and tinnitus.
Northstar has not generated any revenue in the past two years, and the same is expected to continue until late 2008, when it plans to launch its first product. The profitability of the company has also been negative and is expected to remain in red till 2009, one year later from the launch of its first product when it is expected to post some operating profits.
The company is expected to have a difficult path ahead because of the intense competition it faces in the industry. It is expected to face large challenges in developing operational skills and marketing expertise once it launches its first product. Moreover to launch its product it will have to build a strong sales force from scratch which is mountainous task in itself.
Moreover the company faces a huge risk of the failure of its product if the expected clinical results are not favorable enough to support its planned submission to the Food and Drug Administration. Due to the small size of the company and the heavy weight competitors in the market Medtronic, St. Jude, and Boston Scientific, which have many more resources at their disposal, it is not expected that Northstar will show promising results in the coming two years.

RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 3 of 3